The Precision Peptide Genetic Test may help provide context about your predisposition in peptide signaling pathwaysvariants in GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313which can support a more informed conversation with your provider about medication choice and expected dosing needs
doi:10.1056/NEJMcp0801447 Okobi OE, Udoete IO, Fasehun OO, et al
Rapid glycemic improvement with GLP-1 therapy is one of the most powerful benefits of modern diabetes care, but it can also create new clinical challenges
Cell , 64 , 835-849, doi: 10.1016/j.molcel.2016.09.037
Glossary CLBP chronic low back pain CKD chronic kidney disease CNS central nervous system CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF heart failure HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor sNDA supplemental New Drug Application T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus U.S
Both Vyvanse and Concerta are FDA-approved to treat: attention deficit hyperactivity disorder (ADHD) in adults and in children ages 6 years and older Vyvanse is also FDA-approved to treat: binge eating disorder in adults Drug forms and administration Vyvanse and Concerta are both long-acting drugs that are taken once per day in the morning
